

NEXT SCIENCE®

Notice of change of interests of substantial holder

Sydney, Australia Monday, 6 September 2021, Next Science Limited (ASX:NXS) (**Next Science**) refers to the Notice of Change of Interests of Substantial Holder (**Notice**) lodged by Dr Matthew Myntti today.

Dr Myntti is the founder and Chief Technical Officer of Next Science. He is a dedicated and enthusiastic executive and shareholder committed to Next Science's goal of improving public health through groundbreaking discoveries and effective solutions that combat antimicrobial resistance caused by biofilms.

Dr Myntti needed to sell the shares detailed in the Notice in order to meet the financial obligations pursuant to a matrimonial settlement with his former wife.

In addition to his strong personal and professional commitment to Next Science and its development, Dr Myntti remains a substantial holder of Next Science shares.

Approved and authorised for release by Next Science's Managing Director.

Further information:

Judith Mitchell

Managing Director, Next Science Limited
Phone: +61 2 9375 7989
Email: investorqueries@nextscience.com

Michael Brown

Pegasus Advisory
Phone: +61 400 248 080
Email: mbrown@pegasusadvisory.com.au

About Next Science

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. Established in 2012, the Company's primary focus is on the development and continued commercialisation of its proprietary Xbio technology to reduce the impact of biofilm-based infections in human health. Xbio is a unique, non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its Xbio technology. For further information visit: www.nextscience.com.

Next Science Limited ACN 622 382 549

Suite 1902, Level 19, Tower A, The Zenith, 821 Pacific Highway, Chatswood NSW 2067
www.nextscience.com

For personal use only